Knockdown of E2F5 induces cell death via the TP53‑dependent pathway in breast cancer cells carrying wild‑type TP53

Inagaki,Yoshinori; Wu,Dan; Fujiwara,Kyoko; Ishizuka,Yoshiaki; Oguni,Asako; Tokunaga,Tomohiko; Takayama,Tadateru; Soma,Masayoshi; Fukuda,Noboru; Ozaki,Toshinori; Masuda,Shinobu

doi:10.3892/or.2020.7761

Knockdown of E2F5 induces cell death via the TP53‑dependent pathway in breast cancer cells carrying wild‑type TP53

Authors:
- Yoshinori Inagaki
- Dan Wu
- Kyoko Fujiwara
- Yoshiaki Ishizuka
- Asako Oguni
- Tomohiko Tokunaga
- Tadateru Takayama
- Masayoshi Soma
- Noboru Fukuda
- Toshinori Ozaki
- Shinobu Masuda
View Affiliations

Affiliations: Division of General Medicine, Department of Medicine, Nihon University School of Medicine, Tokyo 173‑0032, Japan, Department of Oncology, The 5th Hospital of Xiamen, Xiamen, Fujian 361101, P.R. China, Department of Pediatric Surgery, Nihon University School of Medicine, Tokyo 173‑0032, Japan, Division of Cell Regeneration and Transplantation, Department of Functional Morphology, Nihon University School of Medicine, Tokyo 173‑8610, Japan, Department of DNA Damage Signaling, Research Center, The 5th Hospital of Xiamen, Xiamen, Fujian 361101, P.R. China, Division of Oncologic Pathology, Department of Pathology and Microbiology, Nihon University School of Medicine, Tokyo 173‑0032, Japan
Published online on: September 10, 2020 https://doi.org/10.3892/or.2020.7761
Pages: 2241-2252

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

E2F transcription factor 5 (E2F5) is a member of the E2F family of transcription factors, which are involved in regulation of various cellular processes, including cellular proliferation, apoptosis, differentiation and DNA damage response. Previously, we reported that E2F5 was aberrantly overexpressed in estrogen receptor (ER)‑negative breast cancer, especially in triple‑negative breast cancer (TNBC). In the present study, it was revealed that E2F5 gene silencing caused a significant reduction in the proliferation rate of breast cancer MCF7 (ER‑positive luminal‑type) and MDA‑MB‑231 (TNBC‑type) cells. Additional experiments demonstrated that E2F5 knockdown triggered cell death of MCF7 cells but not MDA‑MB‑231 cells. As MCF7 and MDA‑MB‑231 cells carry wild‑type and mutant TP53, respectively, and BT474 (ER‑negative, HER2‑positive type) carrying mutant TP53 exhibited similar results to MDA‑MB‑231, the possible effects of E2F5 gene depletion on cell death‑related TP53‑target gene expression were examined. Real‑time RT‑qPCR analysis revealed that knockdown of E2F5 in MCF7 cells stimulated cell death‑related transcription of TP53‑target genes such as BAX, NOXA and PUMA. For MDA‑MB‑231 and BT474 cells, E2F5 gene silencing revealed marginal effects on the expression of TP53 target genes. In addition, silencing of TP53 abrogated the effect of E2F5 silencing in MCF7 cells. Collectively, the present results indicated that E2F5 participated in the carcinogenesis of breast cancer carrying wild‑type TP53 through suppression of TP53, while E2F5 had a pro‑proliferative but not anti‑apoptotic effect on breast cancer with TP53 mutation.

View Figures

View References

1	Ginsburg O, Bray F, Coleman MP, Vanderpuye V, Eniu A, Kotha SR, Sarker M, Huong TT, Allemani C, Dvaladze A, et al: The global burden of women's cancers: A grand challenge in global health. Lancet. 389:847–860. 2017. View Article : Google Scholar : PubMed/NCBI
2	Lalloo F and Evans DG: Familial breast cancer. Clin Genet. 82:105–114. 2012. View Article : Google Scholar : PubMed/NCBI
3	Perou CM, Sørlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, Pollack JR, Ross DT, Johnsen H, Akslen LA, et al: Molecular portraits of human breast tumours. Nature. 406:747–752. 2000. View Article : Google Scholar : PubMed/NCBI
4	Sørlie T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen H, Hastie T, Eisen MB, van de Rijn M, Jeffrey SS, et al: Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA. 98:10869–10874. 2001. View Article : Google Scholar : PubMed/NCBI
5	Sorlie T, Tibshirani R, Parker J, Hastie T, Marron JS, Nobel A, Deng S, Johnsen H, Pesich R, Geisler S, et al: Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci USA. 100:8418–8423. 2003. View Article : Google Scholar : PubMed/NCBI
6	Coussens L, Yang-Feng TL, Liao YC, Chen E, Gray A, McGrath J, Seeburg PH, Libermann TA, Schlessinger J, Francke U, et al: Tyrosine kinase receptor with extensive homology to EGF receptor shares chromosomal location with neu oncogene. Science. 230:1132–1139. 1985. View Article : Google Scholar : PubMed/NCBI
7	Akiyama T, Sudo C, Ogawara H, Toyoshima K and Yamamoto T: The product of the human c-erbB-2 gene: A 185-kilodalton glycoprotein with tyrosine kinase activity. Science. 232:1644–1646. 1986. View Article : Google Scholar : PubMed/NCBI
8	Perou CM: Molecular stratification of triple-negative breast cancers. Oncologist. 16 (Suppl 1):S61–S70. 2011. View Article : Google Scholar
9	Xanthoulis A and Tiniakos DG: E2F transcription factors and digestive system malignancies: How much do we know? World J Gastroenterol. 19:3189–3198. 2013. View Article : Google Scholar : PubMed/NCBI
10	Lees JA, Saito M, Vidal M, Valentine M, Look T, Harlow E, Dyson N and Helin K: The retinoblastoma protein binds to a family of E2F transcription factors. Mol Cell Biol. 13:7813–7825. 1993. View Article : Google Scholar : PubMed/NCBI
11	Dyson N: The regulation of E2F by pRB-family proteins. Genes Dev. 12:2245–2262. 1998. View Article : Google Scholar : PubMed/NCBI
12	Stevaux O and Dyson NJ: A revised picture of the E2F transcriptional network and RB function. Curr Opin Cell Biol. 14:684–691. 2002. View Article : Google Scholar : PubMed/NCBI
13	Zhao J, Wu XY, Ling XH, Lin ZY, Fu X, Deng YH, He HC and Zhong W: Analysis of genetic aberrations on chromosomal region 8q21-24 identifies E2F5 as an oncogene with copy number gain in prostate cancer. Med Oncol. 30:4652013. View Article : Google Scholar : PubMed/NCBI
14	Ishimoto T, Shiozaki A, Ichikawa D, Fujiwara H, Konishi H, Komatsu S, Kubota T, Okamoto K, Nakashima S, Shimizu H, et al: E2F5 as an independent prognostic factor in esophageal squamous cell carcinoma. Anticancer Res. 33:5415–5420. 2013.PubMed/NCBI
15	Kothandaraman N, Bajic VB, Brendan PN, Huak CY, Keow PB, Razvi K, Salto-Tellez M and Choolani M: E2F5 status significantly improves malignancy diagnosis of epithelial ovarian cancer. BMC Cancer. 10:642010. View Article : Google Scholar : PubMed/NCBI
16	Lu G, Sun Y, An S, Xin S, Ren X, Zhang D, Wu P, Liao W, Ding Y and Liang L: MicroRNA-34a targets FMNL2 and E2F5 and suppresses the progression of colorectal cancer. Exp Mol Pathol. 99:173–179. 2015. View Article : Google Scholar : PubMed/NCBI
17	Jiang Y, Yim SH, Xu HD, Jung SH, Yang SY, Hu HJ, Jung CK and Chung YJ: A potential oncogenic role of the commonly observed E2F5 overexpression in hepatocellular carcinoma. World J Gastroenterol. 17:470–477. 2011. View Article : Google Scholar : PubMed/NCBI
18	Zou C, Li Y, Cao Y, Zhang J, Jiang J, Sheng Y, Wang S, Huang A and Tang H: Up-regulated MicroRNA-181a induces carcinogenesis in hepatitis B virus-related hepatocellular carcinoma by targeting E2F5. BMC Cancer. 14:972014. View Article : Google Scholar : PubMed/NCBI
19	Donzelli S, Fontemaggi G, Fazi F, Di Agostino S, Padula F, Biagioni F, Muti P, Strano S and Blandino G: MicroRNA-128-2 targets the transcriptional repressor E2F5 enhancing mutant p53 gain of function. Cell Death Differ. 19:1038–1048. 2012. View Article : Google Scholar : PubMed/NCBI
20	Umemura S, Shirane M, Takekoshi S, Kusakabe T, Itoh J, Egashira N, Tokuda Y, Mori K and Osamura YR: Overexpression of E2F-5 correlates with a pathological basal phenotype and a worse clinical outcome. Br J Cancer. 100:764–771. 2009. View Article : Google Scholar : PubMed/NCBI
21	Hijmans EM, Voorhoeve PM, Beijersbergen RL, van't Veer LJ and Bernards R: E2F-5, a new E2F family member that interacts with p130 in vivo. Mol Cell Biol. 15:3082–3089. 1995. View Article : Google Scholar : PubMed/NCBI
22	Gaubatz S, Lindeman GJ, Ishida S, Jakoi L, Nevins JR, Livingston DM and Rempel RE: E2F4 and E2F5 play an essential role in pocket protein-mediated G1 control. Mol Cell. 6:729–735. 2000. View Article : Google Scholar : PubMed/NCBI
23	Bouaoun L, Sonkin D, Ardin M, Hollstein M, Byrnes G, Zavadil J and Olivier M: TP53 Variations in Human Cancers: New Lessons from the IARC TP53 Database and Genomics Data. Hum Mutat. 37:865–876. 2016. View Article : Google Scholar : PubMed/NCBI
24	Polanowska J, Le Cam L, Orsetti B, Vallés H, Fabbrizio E, Fajas L, Taviaux S, Theillet C and Sardet C: Human E2F5 gene is oncogenic in primary rodent cells and is amplified in human breast tumors. Genes Chromosomes Cancer. 28:126–130. 2000. View Article : Google Scholar : PubMed/NCBI
25	Ali A, Ullah F, Ali IS, Faraz A, Khan M, Shah ST, Ali N and Saeed M: Aberrant promoter methylation at CpG cytosines induce the upregulation of the E2F5 gene in breast cancer. J Breast Cancer. 19:133–141. 2016. View Article : Google Scholar : PubMed/NCBI
26	Le Cam L, Polanowska J, Fabbrizio E, Olivier M, Philips A, Ng Eaton E, Classon M, Geng Y and Sardet C: Timing of cyclin E gene expression depends on the regulated association of a bipartite repressor element with a novel E2F complex. EMBO J. 18:1878–1890. 1999. View Article : Google Scholar : PubMed/NCBI
27	Vaishnav YN and Pant V: Differential regulation of E2F transcription factors by p53 tumor suppressor protein. DNA Cell Biol. 18:911–922. 1999. View Article : Google Scholar : PubMed/NCBI
28	Strano S, Dell'Orso S, Mongiovi AM, Monti O, Lapi E, Di Agostino S, Fontemaggi G and Blandino G: Mutant p53 proteins: between loss and gain of function. Head Neck. 29:488–496. 2007. View Article : Google Scholar : PubMed/NCBI
29	Ozaki T and Nakagawara A: Role of p53 in cell death and human cancers. Cancers (Basel). 3:994–1013. 2011. View Article : Google Scholar : PubMed/NCBI
30	Majumder S, Bhowal A, Basu S, Mukherjee P, Chatterji U and Sengupta S: Deregulated E2F5/p38/SMAD3 circuitry reinforces the pro-tumorigenic switch of TGFβ signaling in prostate cancer. J Cell Physiol. 231:2482–2492. 2016. View Article : Google Scholar : PubMed/NCBI